{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:40:21Z","timestamp":1780076421839,"version":"3.54.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003747","name":"Department of Health, State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.025","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T08:18:38Z","timestamp":1705911518000},"page":"1108-1115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-0361","authenticated-orcid":false,"given":"Hazel J.","family":"Clothier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-049X","authenticated-orcid":false,"given":"Aishwarya N.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Mesfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim P.","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vaccine.2024.01.025_b0005","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2024.01.025_b0010","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2021.03.004","article-title":"Developing standard safety outcomes for COVID-19 vaccines","volume":"39","author":"Buttery","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.025_b0015","unstructured":"World Health Organization. COVID-19 vaccines: safety surveillance manual 2021 [accessed 13 November 2023]. [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240032781]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0020","unstructured":"Law B. SO2-D2. 1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020 [accessed 9 November 2023]. [Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2023\/05\/SO2_D2.1.2_V1.2_COVID-19_AESI-update_V1.3.pdf]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0025","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance(ENCePP). Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines 2021 [accessed 13 November 2023]. [Available from: https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=37274]."},{"issue":"19","key":"10.1016\/j.vaccine.2024.01.025_b0030","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2024.01.025_b0035","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.025_b0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2024.01.025_b0045","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine\u2014United States, march\u2013april 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR-Morbidity and mortality weekly report"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.025_b0050","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.025_b0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5694\/mja2.51662","article-title":"Vaccine safety: what systems are required to ensure public confidence in vaccines?","volume":"217","author":"Cheng","year":"2022","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.025_b0060","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries","volume":"27","author":"Sol\u00eds Arce","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.025_b0065","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/imj.15599","article-title":"COVID-19 vaccine hesitancy: a unique set of challenges","volume":"51","author":"Danchin","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.vaccine.2024.01.025_b0070","unstructured":"World Health Organization. Monkeypox - United Kingdom of Great Britain and Northern Ireland 2022 [accessed 13 November 2023]. [Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON381]."},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.025_b0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.nrl.0000138998.11209.88","article-title":"Anticipating smallpox and monkeypox outbreaks: complications of the smallpox vaccine","volume":"10","author":"Abrahams","year":"2004","journal-title":"Neurologist"},{"issue":"9707","key":"10.1016\/j.vaccine.2024.01.025_b0080","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.025_b0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/fampra\/cmv085","article-title":"Medical engagement and organizational characteristics in general practice","volume":"33","author":"Ahnfeldt-Mollerup","year":"2016","journal-title":"Fam Pract"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.025_b0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5694\/mja12.11751","article-title":"Human papillomavirus vaccine in boys: background rates of potential adverse events","volume":"198","author":"Clothier","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2024.01.025_b0095","first-page":"345","article-title":"Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.025_b0100","article-title":"Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study","author":"Li","year":"2021","journal-title":"Medrxiv[Preprint]"},{"issue":"22","key":"10.1016\/j.vaccine.2024.01.025_b0105","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2023.04.041","article-title":"Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines","volume":"41","author":"Pillsbury","year":"2023","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.025_b0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2024.01.025_b0115","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1016\/j.vaccine.2021.10.030","article-title":"Immune thrombocytopenia following immunisation with vaxzevria ChadOx1-S (AstraZeneca) vaccine, victoria, Australia","volume":"39","author":"Gordon","year":"2021","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2024.01.025_b0120","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1016\/j.vaccine.2022.10.084","article-title":"Guillain-Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Australia","volume":"40","author":"Osowicki","year":"2022","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2024.01.025_b0125","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational Global Vaccine Data Network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2024.01.025_b0130","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"US Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.025_b0135","unstructured":"Australian Government Department of Health and Aged Care. National Immunisation Program Schedule [updated 12 July 2023; accessed 9 November 2023]. [Available from: https:\/\/www.health.gov.au\/topics\/immunisation\/when-to-get-vaccinated\/national-immunisation-program-schedule]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0140","unstructured":"Department of Health. Victorian Admitted Episodes Dataset [accessed 9 November 2023]. [Available from: https:\/\/www.health.vic.gov.au\/data-reporting\/victorian-admitted-episodes-dataset]."},{"issue":"303\u20137","key":"10.1016\/j.vaccine.2024.01.025_b0145","article-title":"What a comprehensive, integrated data strategy looks like: the population level analysis and reporting (POLAR)","volume":"264","author":"Pearce","year":"2019","journal-title":"Program Stud Health Technol Inform"},{"key":"10.1016\/j.vaccine.2024.01.025_b0150","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD) 2023 [accessed 13 November 2023]. [Available from: https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0155","unstructured":"SPEAC. The safety platform for emergency vaccines [accessed 9 November 2023]. [Available from: https:\/\/speacsafety.net\/]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0160","unstructured":"VAC4EU. VAccine monitoring Collaboration for Europe 2019 [accessed 9 November 2023]. [Available from: https:\/\/vac4eu.org\/]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0165","first-page":"279","article-title":"SNOMED-CT: The advanced terminology and coding system for eHealth","volume":"121","author":"Donnelly","year":"2006","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.vaccine.2024.01.025_b0170","doi-asserted-by":"crossref","unstructured":"Victorian Department of Health COVID-19 writing group. Population-based analysis of the epidemiological features of COVID-19 epidemics in Victoria, Australia, January 2020 - March 2021, and their suppression through comprehensive control strategies. Lancet Reg Health West Pac. 2021;17:100297:10.1016\/j.lanwpc.2021.100297:PMC8547897.","DOI":"10.1016\/j.lanwpc.2021.100297"},{"key":"10.1016\/j.vaccine.2024.01.025_b0175","unstructured":"Australian Bureau of Statistics. Census [accessed 9 November 2023]. [Available from: https:\/\/www.abs.gov.au\/]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0180","doi-asserted-by":"crossref","unstructured":"Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Medical care. 2007:S89-S95:10.1097\/MLR.0b013e3180616c0a.","DOI":"10.1097\/MLR.0b013e3180616c0a"},{"key":"10.1016\/j.vaccine.2024.01.025_b0185","doi-asserted-by":"crossref","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25(2):215-22:10.1002\/pds.3918:PMC5063172.","DOI":"10.1002\/pds.3918"},{"key":"10.1016\/j.vaccine.2024.01.025_b0190","doi-asserted-by":"crossref","unstructured":"Russek M, Quinten C, de Jong VMT, Cohet C, Kurz X. Assessing heterogeneity of electronic health-care databases: A case study of background incidence rates of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2023;32(9):1032-48:10.1002\/pds.5631.","DOI":"10.1002\/pds.5631"},{"key":"10.1016\/j.vaccine.2024.01.025_b0195","doi-asserted-by":"crossref","unstructured":"Chiu N-C, Chi H, Tai Y-L, Peng C-C, Tseng C-Y, Chen C-C, et al. Impact of wearing masks, hand hygiene, and social distancing on influenza, enterovirus, and all-cause pneumonia during the coronavirus pandemic: retrospective national epidemiological surveillance study. Journal of medical Internet research. 2020;22(8):e21257:10.2196\/21257:PMC7471891.","DOI":"10.2196\/21257"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.025_b0200","first-page":"e001065","article-title":"Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review. BMJ","volume":"4","author":"Mesfin","year":"2019","journal-title":"Global Health"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.025_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjhci-2019-100009","article-title":"Coding and classifying GP data: the POLAR project","volume":"26","author":"Pearce","year":"2019","journal-title":"BMJ health & care informatics"},{"issue":"100894","key":"10.1016\/j.vaccine.2024.01.025_b0210","article-title":"The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study","volume":"40","author":"Tran","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1053637","key":"10.1016\/j.vaccine.2024.01.025_b0215","article-title":"Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline. Front","volume":"10","author":"Laemmle-Ruff","year":"2022","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2024.01.025_b0220","unstructured":"Autralian Government Department of Health and Aged Care. National Immunisation Program \u2013 changes to shingles vaccination from 1 November 2023 [accessed 9 November 2023]. [Available from: https:\/\/www.health.gov.au\/news\/national-immunisation-program-changes-to-shingles-vaccination-from-1-november-2023]."},{"issue":"338","key":"10.1016\/j.vaccine.2024.01.025_b0225","article-title":"Syndromic surveillance for influenza in two hospital emergency departments. Relationships between ICD-10 codes and notified cases, before and during a pandemic","volume":"11","author":"Moore","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.01.025_b0230","unstructured":"Centre for Disesase Control (CDC). Vaccine Safety Datalink (VSD) [accessed 9 November 2023]. [Available from: https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0235","unstructured":"Centre for Health Analytics. Vaccine Safety Health Link (VSHL)-Near real-time automated vaccine safety signal detection using routinely collected healthcare data [accessed 13 November 2023]. [Available from: https:\/\/www.healthanalytics.org.au\/directory\/vshl\/]."},{"key":"10.1016\/j.vaccine.2024.01.025_b0240","doi-asserted-by":"crossref","unstructured":"Flores LE, Frontera WR, Andrasik MP, Del Rio C, Mondr\u00edguez-Gonz\u00e1lez A, Price SA, et al. Assessment of the inclusion of racial\/ethnic minority, female, and older Individuals in vaccine clinical trials. JAMA Netw Open. 2021;4(2):e2037640:10.1001\/jamanetworkopen.2020.37640:PMC7896193.","DOI":"10.1001\/jamanetworkopen.2020.37640"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.025_b0245","doi-asserted-by":"crossref","first-page":"e039097","DOI":"10.1136\/bmjopen-2020-039097","article-title":"Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data","volume":"10","author":"Simpson","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.025_b0250","doi-asserted-by":"crossref","first-page":"e026299","DOI":"10.1136\/bmjopen-2018-026299","article-title":"Understanding non-vaccinating parents\u2019 views to inform and improve clinical encounters: a qualitative study in an Australian community","volume":"9","author":"Helps","year":"2019","journal-title":"BMJ Open"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:32Z","timestamp":1759404812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000252"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}